Thromb Haemost 2000; 84(02): 352-354
DOI: 10.1055/s-0037-1614021
Letters to the Editor
Schattauer GmbH

Absence of Circulating Factor IX Antigen in Hemophilia B Dogs of the UNC-Chapel Hill Colony

Roland W. Herzog
1   From the Departments of Pediatrics and Pathology, University of Pennsylvania Medical Center and The Children’s Hospital of Philadelphia, Philadelphia, PA, USA
,
Valder R. Arrada
1   From the Departments of Pediatrics and Pathology, University of Pennsylvania Medical Center and The Children’s Hospital of Philadelphia, Philadelphia, PA, USA
,
Thomas H. Fisher
2   Departments of Medicine, Chapel Hill, NC, USA
,
Marjorie S. Read
3   Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
,
Timothy C. Nichols
3   Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
,
Katherine A. High
1   From the Departments of Pediatrics and Pathology, University of Pennsylvania Medical Center and The Children’s Hospital of Philadelphia, Philadelphia, PA, USA
4   Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, PA, USA
› Author Affiliations
Further Information

Publication History

Received 26 January 2000

Accepted 02 February 2000

Publication Date:
14 December 2017 (online)

 

 
  • References

  • 1 Evans JP, Brinkhous KM, Brayer GD, Reisner HW, High KA. Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Aci USA 1989; 86: 10095-99.
  • 2 Kay MA, Rothenberg S, Landen CN, Bellinger DA, Leland F, Toman C, Finegold M, Thompson AR, Read MS, Brinkous KM, Woo SLC. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficientdogs. Science 1993; 262: 117-9.
  • 3 Kay MA, Landen CN, Rothenberg SR, Taylor LA, Leland F, Wiehle S, Fang B, Bellinger D, Finegold M, Thompson AR. et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994; 91: 2353-7.
  • 4 Fang B, Wang H, Gordon G, Bellinger DA, Read MS, Brinkhous KM, Woo SLC, Eisensmith RC. Lack of persistent of El- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dog. Gene Ther 1996; 03: 217-22.
  • 5 Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, Burton M, Bellinger DA, Read MS, Brinkhous KM, Podsakoff GM, Nichols TC, Kurtzman GJ, High KA. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 05: 56-63.
  • 6 Synder RO, Miao C, Meuse L, Tubb J, Donahue BA, Lin H-F, Stafford DW, Patel S, Thompson AR, Nichols T, Read MS, Bellinger DA, Brinkhous KM, Kay MA. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 1999; 05: 64-70.
  • 7 Chao H, Walsh CE. Endogenous FIX antigen exists in Chapel Hill strain hemophilia B canine. Thromb Haemost 1999; 82: 1378.
  • 8 Sugahara Y, Catelfamo J, Brooks M, Hitomi E, Bajaj SP, Kurachi K. Isolationand characterization of canine factor IX. Thromb Haemost 1996; 75: 450-55.
  • 9 Green PM. et al. Haemophilia B: database of point mutations and short additions and delitions—v9.0. http://www.umds.acuk/molgen (1999)
  • 10 O’Farrell P. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975; 250: 4007-21.
  • 11 White T, Lacal J, Reep B, Fischer T, Lapetina E, White G. Thrombolamban, the 22 kilodalton platelet substrate of c AMP-dependent protein kinase, is immunologically homologous with the ras family of GTP-binding proteins. Proc Natl Acad Sci USA 1990; 87: 758-62.